Lifecore Biomedical, Inc. \De\ (LFCR) Cash & Equivalents (2010 - 2025)

Lifecore Biomedical, Inc. \De\'s Cash & Equivalents history runs 16 years deep, the most recent figure standing at $8.3 million for Q2 2025.

• In Q2 2025, Cash & Equivalents fell 2.33% year-over-year to $8.3 million; the TTM figure through May 2025 stood at $8.3 million (down 2.33% YoY), while the FY2025 annual figure was $8.3 million, down 2.33% from the prior year.
• Cash & Equivalents for Q2 2025 stood at $8.3 million, up from $5.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $19.1 million in Q2 2023, with the low at $609000.0 in Q4 2021.
• The 5-year median for Cash & Equivalents is $2.7 million (2022), against an average of $4.9 million.
• The sharpest annual moves came in 2021 and 2023: Cash & Equivalents slumped 75.4% in 2021, then surged 1826.44% in 2023.
• Lifecore Biomedical, Inc. \De\'s Cash & Equivalents stood at $609000.0 in 2021, then jumped by 875.04% to $5.9 million in 2022, then surged by 221.51% to $19.1 million in 2023, then sank by 50.47% to $9.5 million in 2024, then retreated by 12.59% to $8.3 million in 2025.
• Business Quant data shows LFCR's Cash & Equivalents at $8.3 million in Q2 2025, $5.4 million in Q1 2025, and $9.5 million in Q4 2024.